93例胰腺导管腺癌患者的临床预后分析  

Analysis of 93 cases of pancreatic ductal adenocarcinoma clinical prognosis

作　　者：高杨[1] 张升宁[1] 张熙冰 莽源祎 李立[1] 冉江华[1] GAO Yang;ZHANG Shengning;ZHANG Xibing;MANG Yuanyi;LI Li;RAN Jianghua(Hepatobiliary Pancreatic and Vascular Surgery,First Hospital of Kunming,The Affiliated Calmette Hospital of Kunming Medical University,Organ Transplantation Research Institute of Yunnan,Kunming,Yunnan,650000,China)

机构地区：[1]昆明市第一人民医院,昆明医科大学附属甘美医院肝胆胰血管外科,云南省器官移植研究所,云南昆明650000

出　　处：《当代医学》2021年第3期1-6,共6页Contemporary Medicine

摘　　要：目的探讨影响胰腺癌患者预后的相关因素。方法回顾性分析93例胰腺患者的临床分期、病理分化、手术情况、CA199指标、是否化疗等情况,分析其对患者预后的影响。结果93例胰腺癌患者中位无瘤生存期(median disease free survival,mDFS)为14个月,中位总生存期(median overall survival,mOS)为16.5个月。将肿瘤分期、肿瘤分化程度、术前CA199水平、治疗后CA199是否下降、是否达到R0切除、是否进行淋巴结清扫、是否新辅助化疗进行COX回归多因素分析,均可作为独立因素影响患者DFS和OS(P<0.05)。结论肿瘤分期、分化程度、术前CA199水平、治疗后CA199是否下降可作为判断胰腺癌患者预后的指标,手术中R0切除、淋巴结清扫和新辅助化疗可提高患者预后。Objective To explore the related factors affecting the prognosis of pancreatic ductal adenocarcinoma(PDAC).Methods Review 93 patients of PDAC whose clinical stages,pathological differentiation,surgical approach,CA199 index and neoadjuvant chemotherapy and analyze their prognosis.Results In 93 PDAC patients,the median disease-free survival(mDFS)was 14 months,and the median overall survial(mOS)was 16.5 months.COX multi-variate analysis determined clinical stages,pathological differentiation,R0 resection,lymph node cleaning,CA199 index,and neoadjuvant chemotherapy as independent risk factors for DFS and OS(P<0.05).Conclusion Clinical stages,pathological differentiation,CA199 index can be used as index of judging the prognosis of patients with PDAC,R0 resection,lymph node cleaning and neoadjuvant chemotherapy can improve the prognosis of patients.

关 键 词：胰腺导管腺癌 预后 分析 

分 类 号：R735.9[医药卫生—肿瘤]